Emergent Biosolutions (NYSE:EBS) PT Raised to $75.00

Emergent Biosolutions (NYSE:EBS) had its price objective upped by Cantor Fitzgerald from $68.00 to $75.00 in a report published on Friday, November 2nd, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Goldman Sachs Group upgraded shares of Emergent Biosolutions from a neutral rating to a buy rating and upped their target price for the company from $60.00 to $75.00 in a report on Friday, November 2nd. Argus upped their target price on shares of Emergent Biosolutions to $70.00 and gave the company an average rating in a report on Tuesday, September 11th. They noted that the move was a valuation call. Chardan Capital upped their target price on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the company a buy rating in a report on Tuesday, September 4th. Cowen restated a hold rating and issued a $49.00 target price on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 target price on shares of Emergent Biosolutions and gave the company a hold rating in a report on Wednesday, August 29th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $66.25.

EBS traded down $0.02 during trading hours on Friday, hitting $67.54. 285,122 shares of the company’s stock were exchanged, compared to its average volume of 370,379. Emergent Biosolutions has a 12-month low of $36.38 and a 12-month high of $71.01. The company has a market cap of $3.54 billion, a P/E ratio of 35.55, a PEG ratio of 1.58 and a beta of 1.27. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.07). Emergent Biosolutions had a net margin of 14.19% and a return on equity of 12.89%. The firm had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. During the same period in the prior year, the company posted $0.73 earnings per share. The company’s revenue for the quarter was up 16.3% on a year-over-year basis. Research analysts forecast that Emergent Biosolutions will post 2.2 earnings per share for the current year.

In other Emergent Biosolutions news, EVP Adam Havey sold 22,996 shares of the company’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $61.06, for a total transaction of $1,404,135.76. Following the completion of the transaction, the executive vice president now owns 36,079 shares in the company, valued at approximately $2,202,983.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronald Richard sold 7,893 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total transaction of $473,737.86. Following the transaction, the director now owns 21,063 shares of the company’s stock, valued at approximately $1,264,201.26. The disclosure for this sale can be found here. In the last quarter, insiders have sold 199,943 shares of company stock valued at $12,115,228. 16.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Sei Investments Co. increased its holdings in shares of Emergent Biosolutions by 5,992.1% in the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,775 shares in the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in shares of Emergent Biosolutions in the 2nd quarter valued at about $202,000. Parametrica Management Ltd purchased a new position in shares of Emergent Biosolutions in the 3rd quarter valued at about $223,000. Family Firm Inc. purchased a new position in shares of Emergent Biosolutions in the 3rd quarter valued at about $225,000. Finally, Intrust Bank NA purchased a new position in shares of Emergent Biosolutions in the 2nd quarter valued at about $234,000. Institutional investors and hedge funds own 82.76% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: What does relative strength index mean?

The Fly

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply